You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

daratumumab subcutaneous (sc)

Showing 1 - 25 of 7,339
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC With STK11/LKB1 Mutation Trial in New York (Daratumumab and Hyaluronidase-fihj, Pre-Intervention Medication,

Not yet recruiting
  • Non-small Cell Lung Cancer With STK11/LKB1 Mutation
  • Daratumumab and Hyaluronidase-fihj
  • +2 more
  • New York, New York
    NYU Langone Health
Mar 29, 2023

Multiple Myeloma Trial in Worldwide (Daratumumab Subcutaneous (SC) Administration, Recombinant Human Hyaluronidase [rHuPH20]) SC

Active, not recruiting
  • Multiple Myeloma
  • Daratumumab Subcutaneous (SC) Administration
  • Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
  • Atlanta, Georgia
  • +11 more
Aug 11, 2022

Relapsed or Refractory Multiple Myeloma Trial in Germany, Spain, United States (INCB001158, Daratumumab SC)

Completed
  • Relapsed or Refractory Multiple Myeloma
  • Daphne, Alabama
  • +28 more
May 5, 2022

Multiple Myeloma Trial in Miami (Teclistamab, Talquetamab, Daratumumab SC)

Not yet recruiting
  • Multiple Myeloma
  • Miami, Florida
    University of Miami
Oct 20, 2023

Patient and Healthcare Provider Satisfaction of Daratumumab Use

Recruiting
  • Multiple Myeloma
  • +5 more
  • Daratumumab
  • Frankfurt, Hessen, Germany
    Centrum für Hämatologie und Onkologie Bethanien
Aug 1, 2022

Multiple Myeloma Trial run by the National Cancer Institute (NCI) (Dexamethasone, Carfilzomib, Daratumumab)

Recruiting
  • Multiple Myeloma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Proliferative Glomerulonephritis With Monoclonal IgG Deposits Trial in Rochester (Daratumumab)

Not yet recruiting
  • Proliferative Glomerulonephritis With Monoclonal IgG Deposits
  • Rochester, Minnesota
    Mayo Clinic Minnesota
Dec 8, 2022

Lymphoma, Primary Effusion Trial run by the National Cancer Institute (NCI) (Daratumumab SC)

Not yet recruiting
  • Lymphoma, Primary Effusion
  • Daratumumab SC
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 23, 2023

Multiple Myeloma Trial in Worldwide (Carfilzomib 20 mg/m^2, Carfilzomib 70 mg/m^2, Dexamethasone 40 mg)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib 20 mg/m^2
  • +4 more
  • Gilbert, Arizona
  • +107 more
Dec 20, 2022

AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease Trial in San Francisco (Venetoclax, Dexamethasone,

Not yet recruiting
  • AL Amyloidosis
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Aug 16, 2022

AL Amyloidosis Trial in Beijing

Recruiting
  • AL Amyloidosis
    • Beijing, China
      Peking Union Medical College Hospital
    Apr 20, 2022

    Allosensitization, Heart Transplant Failure and Rejection Trial in Stanford (Daratumumab-SC)

    Recruiting
    • Allosensitization
    • Heart Transplant Failure and Rejection
    • Stanford, California
      Stanford Health Care
    Sep 20, 2021

    Trial (Daratumumab)

    Approved for marketing
      • (no location specified)
      Jul 3, 2020

      Newly Diagnosed Multiple Myeloma Trial in New York (Daratumumab, Bortezomib, Lenalidomide)

      Recruiting
      • Newly Diagnosed Multiple Myeloma
      • New York, New York
        Icahn School of Medicine at Mount Sinai
      Dec 29, 2022

      Multiple Myeloma Trial (Dara-SC, Blood for research assessments, Bone marrow for research assessments)

      Withdrawn
      • Multiple Myeloma
      • Dara-SC
      • +2 more
      • (no location specified)
      Jan 6, 2022

      Relapsed or Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Daratumumab, Pomalidomide)

      Not yet recruiting
      • Relapsed or Refractory Multiple Myeloma
      • Tucson, Arizona
      • +191 more
      Aug 11, 2022

      NSCLC Trial (Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • Tislelizumab IV
      • +2 more
      • (no location specified)
      Oct 25, 2023

      Alzheimer Trial in Daejeon (GB-5001A, GB-5001D, Oral cohort)

      Recruiting
      • Alzheimer Disease
      • Daejeon, Korea, Republic of
        Chungnam National University Hospital
      Nov 17, 2023

      A 24-month Real Life PErsistence Efficacy and Safety Study in

      Recruiting
      • Inflammatory Bowel Diseases
      • Subcutaneous infliximab CT-P13 Remsima®SC
      • Grenoble, France
        Nicolas Mathieu
      Aug 2, 2022

      Alzheimer Trial in Manhasset (Daratumumab Injection)

      Recruiting
      • Alzheimer Disease
      • Daratumumab Injection
      • Manhasset, New York
        The Litwin-Zucker Research Center
      Nov 16, 2021

      Multiple Myeloma Trial in Worldwide (Daratumumab, Pomalidomide, Dexamethasone)

      Recruiting
      • Multiple Myeloma
      • Birmingham, Alabama
      • +198 more
      Jan 17, 2023

      Crohn's Disease Trial (Risankizumab SC, Placebo for risankizumab)

      Not yet recruiting
      • Crohn's Disease
      • Risankizumab SC
      • Placebo for risankizumab
      • (no location specified)
      Sep 26, 2023

      Crohn's Disease Trial in Warszawa (CT-P13 SC (Infliximab), Placebo SC)

      Active, not recruiting
      • Crohn's Disease
      • CT-P13 SC (Infliximab)
      • Placebo SC
      • Warszawa, Poland
        WIP Warsaw IBD Point Profesor Kierkus
      Dec 6, 2022

      Myositis Trial (EFG PH20 SC)

      Not yet recruiting
      • Myositis
      • EFG PH20 SC
      • (no location specified)
      Jul 28, 2023

      Multiple Myeloma Trial in Worldwide (Dara SC, Dara IV)

      Active, not recruiting
      Has Results
      • Multiple Myeloma
      • Dara SC
      • Dara IV
      • Boston, Massachusetts
      • +145 more
      Jan 17, 2023